Study guide

9.1 MNT for Cardiovascular Disease, Hypertension, and Dyslipidemia

Nutritionist-Dietitian Licensure Examination NDLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Licensure Law, Ethics, and the Clinical Nutritionist-Dietitian

1.1 NDLE Format, Scoring Rules, and RA 10862 Licensure Requirements 1.2 Scope of Practice, Professional Ethics, and Discipline under RA 10862 1.3 Role of the Clinical Nutritionist-Dietitian, Diet Orders, and Standard Hospital Diets

2 Chapter 2: Anatomy and Physiology for Nutrition I

2.1 Cells, Tissues, Membranes, and the Immune and Lymphatic Systems 2.2 The Digestive System: Organs, Enzymes, GI Hormones, and the Liver 2.3 Endocrine and Nervous System Regulation of Metabolism and Appetite

3 Chapter 3: Anatomy and Physiology II, Energy, and Carbohydrate Metabolism

3.1 Cardiovascular, Respiratory, Renal, Musculoskeletal, and Reproductive Systems 3.2 Energy Metabolism and Energy Expenditure Calculations 3.3 Carbohydrate Chemistry, Digestion, and Glycemic Pathways

4 Chapter 4: Protein, Lipid, Mineral, and Fluid Biochemistry

4.1 Protein Chemistry, Amino Acid Metabolism, and Nitrogen Balance 4.2 Lipid Metabolism, Lipoproteins, and Cardiovascular Biomarkers 4.3 Minerals, Water, Electrolytes, and Acid-Base Balance

5 Chapter 5: Basic Nutrition: Vitamins, Minerals, and the PDRI

5.1 Vitamin Biochemistry: Coenzyme Functions and Deficiency Syndromes 5.2 Vitamins and Minerals: PDRI Values, Food Sources, Bioavailability, Stability, and Toxicity 5.3 Philippine Dietary Reference Intakes (PDRI 2015), Pinggang Pinoy, and Dietary Guidelines

6 Chapter 6: Diet Computation and Clinical Nutrition Assessment

6.1 Food Exchange Lists, Meal Plan Computation, Food Labels, and Nutrient Density 6.2 Computing Desirable Body Weight, Total Energy Requirement, and the Diet Prescription 6.3 ABCD Methods of Clinical Nutrition Assessment

7 Chapter 7: Nutrition Diagnosis, Life-Stage Assessment, and Laboratory Data

7.1 Nutrition Diagnosis, PES Statements, and Medical Record Documentation 7.2 Pediatric, Obstetric, and Geriatric Clinical Nutritional Assessment 7.3 Interpreting Biochemical and Laboratory Data in Nutrition Assessment

8 Chapter 8: Drug-Nutrient Interactions, Diabetes, and Weight Disorders

8.1 Drug-Nutrient Interactions and Nutrient Depletion 8.2 MNT for Diabetes Mellitus and Endocrine Disorders 8.3 MNT for Overweight, Obesity, and Underweight

9 Chapter 9: MNT for Cardiovascular, Renal, and Gastrointestinal Disease

9.1 MNT for Cardiovascular Disease, Hypertension, and Dyslipidemia 9.2 MNT for Renal Diseases (AKI, CKD Stages 1-5, Dialysis, and Nephrotic Syndrome) 9.3 MNT for Disorders of the Gastrointestinal Tract

10 Chapter 10: MNT for Liver, Infectious, Respiratory, Allergic, and Neurologic Conditions

10.1 MNT for Liver, Gallbladder, and Pancreatic Disorders 10.2 MNT for Fevers, Infections, Diarrheal Disease, and Respiratory Disorders 10.3 MNT for Food Allergy and Intolerance, Skin, Rheumatic, Musculoskeletal, and Neurologic Disorders

11 Chapter 11: Critical Illness, Oncology, HIV, and Protein-Energy Malnutrition

11.1 MNT in Critical Illness, Sepsis, Trauma, and Burns 11.2 MNT in Oncology: Cancer Cachexia and Treatment Side Effects 11.3 MNT for HIV/AIDS and for Protein-Energy Malnutrition in Children and Adults

12 Chapter 12: Metabolic Disorders, Dysphagia, and Enteral Nutrition

12.1 MNT for Inborn Errors of Metabolism and Eating Disorders 12.2 Dysphagia, IDDSI Texture-Modified Diets, and Adaptive Feeding 12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications

13 Chapter 13: Parenteral Nutrition, Refeeding, and Nutrition Counseling

13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding 13.2 Refeeding Syndrome and Complications of Parenteral Nutrition 13.3 Nutrition Counseling and Behavior Change Theories

14 Chapter 14: Nutrition Updates: Supplements, Diet Trends, and Sports Nutrition

14.1 Dietary Supplements, Herbal Medicines, and Functional Foods 14.2 Vegetarian Diets, Protein Complementation, and Popular Diet Trends 14.3 Sports Nutrition and Workplace Wellness Programs

15 Chapter 15: Community Nutrition and Population Assessment

15.1 Community Nutrition Principles, the ND's Roles, and the Philippine Health Delivery System 15.2 Nutritional Epidemiology and Health Status Indicators in the Philippines 15.3 Assessment of Community Nutritional Status and Operation Timbang Plus (OPT+)

16 Chapter 16: Dietary Surveys, Nutrition Research, and Surveillance

16.1 Food Consumption Surveys, Biochemical Tests in Surveys, and Clinical Signs of Deficiency 16.2 Food and Nutrition Research Methods, Sampling, Sample Size, and Research Ethics 16.3 National Nutrition Surveys, Demographic Data, and Designing a Nutrition Surveillance System

17 Chapter 17: Nutrition Education and Program Evaluation

17.1 Nutrition Education: Definition, Principles of Learning, Methods, and Teaching Aids 17.2 Designing a Nutrition Education Program and Measuring Customer Satisfaction 17.3 Program Planning Cycle, SMART Objectives, and Types of Evaluation

18 Chapter 18: Program Planning, Interventions, and Food Security

18.1 Nutrition Program Planning: Needs, Priorities, Constraints, Goals, and Using Evaluation Results 18.2 Nutrition Interventions and Programs for Specific Population Groups 18.3 Food and Nutrition Security, Dietary Diversity, and Vulnerable Populations

19 Chapter 19: Nutrition Governance, Networking, and Program History

19.1 National Nutrition Council (NNC) Structure and Philippine Plan of Action for Nutrition (PPAN) 19.2 Nutrition Agencies, Networking, Community Linkages, Teamwork, and Nutrition Legislation 19.3 Development of Philippine Nutrition Programs and the Country's Nutrition Problems

20 Chapter 20: Fortification, Feeding, and First 1,000 Days Laws

20.1 Food Fortification (RA 8976), Salt Iodization (RA 8172), and the 2024 Salt Industry Law 20.2 Supplementary Feeding Programs (RA 11037) and DSWD/DepEd Interventions 20.3 First 1,000 Days Law (RA 11148) and Maternal-Child Interventions

21 Chapter 21: Nutrition in the Life Cycle I

21.1 Infant and Young Child Feeding (IYCF), Philippine Milk Code (EO 51), and RA 10028 21.2 Nutrition in Pregnancy and Lactation: Physiology, Needs, Meal Patterns, and Problems 21.3 Nutrition from Infancy to School Age: Growth, Feeding Patterns, Problems, and School Programs

22 Chapter 22: Nutrition in the Life Cycle II

22.1 Nutrition for Adolescents and Adults: Growth Spurt, Risk Factors, and NCD Prevention 22.2 Nutrition for Older Adults: Aging Changes, Needs, Problems, and Senior Citizen Programs

23 Chapter 23: Food Science and Plant Foods

23.1 Chemistry of Starches, Proteins, Lipids, and Emulsions in Cooking 23.2 Food Pigments, Flavor Chemistry, and Browning Reactions (Maillard & Enzymatic) 23.3 Fruits, Vegetables, and Legumes: Classification, Market Forms, Quality, Storage, and Cookery

24 Chapter 24: Animal Foods, Cereals and Baking, and Cooking Methods

24.1 Meat, Poultry, Fish, Eggs, and Milk: Structure, Quality, Storage, and Cookery 24.2 Cereals, Flour Mixtures and Baking, Sugar Cookery, Fats and Oils, and Beverages 24.3 Heat Transfer, Dry-Heat and Moist-Heat Cooking Methods, and Filipino Cooking Techniques

25 Chapter 25: Culinary Skills, Family Meal Planning, and Food Quality

25.1 Culinary Vocabulary, Knife Cuts, Basic Sauces, and Accurate Measurement 25.2 Meal Planning for the Family, Food Budgeting, and Recipe Development 25.3 Sensory Evaluation, Objective Food Tests, and Quality Assurance in Food Production

26 Chapter 26: Food Microbiology, Preservation, and Food Law

26.1 Foodborne Pathogens, Microbial Kinetics, and FAT TOM Parameters 26.2 Food Preservation Methods, Thermal Processing, and Packaging 26.3 Philippine Food Laws, Regulatory Agencies, and Food Labeling

27 Chapter 27: Sanitation, HACCP, Waste, and Workplace Safety

27.1 Sanitation Standard Operating Procedures (SSOP) and Good Manufacturing Practices (GMP) 27.2 HACCP Principles and Critical Control Point Management in Food Service 27.3 Waste Management, Pest Control Regulation, and Occupational Safety in Food Service

28 Chapter 28: Food Service Systems, Production Planning, and Menus

28.1 Types of Food Service Delivery Systems (Conventional, Ready-Prepared, Commissary, Assembly) 28.2 Forecasting, Production Planning, and Quantity Food Production Techniques 28.3 Institutional Menu Planning, Modified Diets, and Recipe Standardization

29 Chapter 29: Distribution, Purchasing, and Storage

29.1 Food Distribution and Service Systems in Hospitals and Other Institutions 29.2 Food Purchasing Methods, Specifications, and Receiving 29.3 Storage Management, Inventory Control, and Valuation

30 Chapter 30: Cost Control, Financial Management, and Facility Layout

30.1 Food Cost Accounting, Yield Testing, and Portion Control Formulas 30.2 Menu Pricing Models, Break-Even Analysis, and Financial Statements 30.3 Food Service Facility Layout, Equipment Selection, and Workflow Ergonomics

31 Chapter 31: Equipment, Management, and Human Resources

31.1 Food Service Equipment: Selection, Capacity, Life-Cycle Cost, Depreciation, and Maintenance 31.2 Management Functions, Theories, Leadership Styles, and Managing Change in Food Service 31.3 Human Resource Management: Job Design, Recruitment, Training, Appraisal, and Discipline

32 Chapter 32: Labor Law, Permits, and Food Service Marketing

32.1 Philippine Labor Laws and Business Permits for Food Service Operations 32.2 Food Service Marketing, Menu Engineering, and Sustainable Food Service

9.1 MNT for Cardiovascular Disease, Hypertension, and Dyslipidemia

Key Takeaways Explain This Topic AI

Atherogenesis begins with endothelial dysfunction and subendothelial LDL oxidation, triggering scavenger receptor macrophage uptake to form foam cells, fatty streaks, and unstable fibrous plaques susceptible to rupture.

The Therapeutic Lifestyle Changes (TLC) diet and Philippine Lipid Guidelines restrict saturated fat to < 7 % < 7\% < 7% of total calories, eliminate trans fats, restrict cholesterol to < 200 mg/day < 200\text{ mg/day} < 200 mg/day , and prescribe 10 – 25 g/day 10–25\text{ g/day} 10–25 g/day of viscous soluble fiber and 2 g/day 2\text{ g/day} 2 g/day of plant stanols/sterols.

Medical nutrition therapy for hypertension enforces sodium restrictions of < 2,300 mg/day < 2{,}300\text{ mg/day} < 2 , 300 mg/day (standard) or < 1,500 mg/day < 1{,}500\text{ mg/day} < 1 , 500 mg/day (strict) and implements the DASH eating plan, providing 4,700 mg/day 4{,}700\text{ mg/day} 4 , 700 mg/day potassium, 1,240 mg/day 1{,}240\text{ mg/day} 1 , 240 mg/day calcium, and 500 mg/day 500\text{ mg/day} 500 mg/day magnesium.

Heart failure management requires a 2,000 mg/day 2{,}000\text{ mg/day} 2 , 000 mg/day sodium limit, a 1.5 – 2.0 L/day 1.5–2.0\text{ L/day} 1.5–2.0 L/day fluid restriction in hypervolemia or hyponatremia, and hypercaloric ( 30 – 35 kcal/kg 30–35\text{ kcal/kg} 30–35 kcal/kg ), high-protein ( 1.2 – 1.5 g/kg 1.2–1.5\text{ g/kg} 1.2–1.5 g/kg ) repletion to prevent cardiac cachexia.

Chronic loop diuretic therapy in heart failure accelerates urinary excretion of potassium, magnesium, and thiamin, necessitating biochemical monitoring to prevent secondary thiamin-deficient high-output failure.

Last updated: October 2026

Cardiovascular diseases (CVD) remain the primary cause of morbidity and mortality in the Philippines and globally. Atherosclerotic cardiovascular disease (ASCVD), systemic arterial hypertension, and congestive heart failure share common pathophysiological roots governed by vascular endothelial dysfunction, chronic vascular inflammation, hemodynamic shearing forces, and atherogenic dyslipidemia. Evidence-based Medical Nutrition Therapy directly addresses these cellular and vascular mechanisms to retard disease progression, stabilize vulnerable plaques, and reduce fatal vascular events.

Cellular Pathophysiology of Atherosclerosis

Atherosclerosis is not a simple degenerative disorder of passive lipid accumulation, but an active, chronic inflammatory process affecting large and medium-sized elastic and muscular arteries: +-----------------------------------------------------------------------------------------+

  • | Atherosclerotic Inflammatory Cascade |
  • | |
  • | [Endothelial Injury] -> [LDL Infiltration & Oxidation] -> [Macrophage Scavenger Uptake] |
  • | | |
  • | [Thrombotic Rupture] <- [Unstable Fibrous Cap] <- [Fatty Streak / Foam Cells] <--------+ |
  • +-----------------------------------------------------------------------------------------+

Endothelial Dysfunction: Chronic insults—including elevated oxidized low-density lipoproteins (oxLDL), cigarette smoking toxins, sustained shear stress from arterial hypertension, advanced glycation end-products (AGEs) in diabetes, and hyperhomocysteinemia—impair endothelial nitric oxide (NO) bioavailability. The endothelium expresses cellular adhesion molecules: Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intercellular Adhesion Molecule-1 (ICAM-1).

Lipoprotein Infiltration and Retention: Circulating apolipoprotein B-100 (ApoB) containing lipoproteins, predominantly LDL and remnant particles, penetrate the compromised endothelial barrier and bind to subendothelial matrix proteoglycans in the arterial intima.

Lipid Oxidation: Trapped LDL undergoes oxidation by vascular reactive oxygen species (ROS) and enzymatic lipoxygenases, generating oxidized LDL (oxLDL) . Oxidized LDL acts as a powerful local chemoattractant and cytotoxic agent, stimulating endothelial release of monocyte chemoattractant protein-1 (MCP-1) and macrophage colony-stimulating factor (M-CSF).

Foam Cell Formation: Circulating blood monocytes adhere to VCAM-1, migrate into the intima, and differentiate into active macrophages. Macrophages express scavenger receptors (SR-A, CD36) that engulf oxLDL via unregulated receptor-mediated pinocytosis. Unlike native LDL receptors, scavenger receptors lack negative feedback inhibition, allowing macrophages to become engorged with cholesteryl esters, transforming into lipid-laden foam cells .

Fatty Streak to Fibrous Plaque: Apoptosis of foam cells creates a necrotic lipid core surrounded by cellular debris. Platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF- β \beta β ) released from platelets and macrophages induce vascular smooth muscle cells (VSMCs) to migrate from the media into the intima. VSMCs proliferate and secrete extensive collagen matrix, forming a protective fibrous cap over the necrotic lipid core.

Plaque Rupture and Acute Thrombosis: Macrophages secrete matrix metalloproteinases (MMPs), collagenases, and elastases that degrade interstitial collagen in the fibrous cap. Thinning of the cap makes it vulnerable to mechanical shear stress. Plaque rupture or endothelial erosion exposes highly thrombogenic subendothelial tissue factor and collagen to circulating platelets, activating the coagulation cascade and triggering acute intraluminal thrombus formation, culminating in acute myocardial infarction (AMI) or ischemic cerebrovascular accident (CVA).

Dyslipidemia Classification and Medical Nutrition Therapy

Clinical lipid management adheres to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) Therapeutic Lifestyle Changes (TLC) diet and on Philippine clinical practice guidelines for dyslipidemia:

Standard Plasma Lipid Reference Cutoffs

Lipid Component Desirable / Optimal Borderline High High Risk Threshold Very High Risk

Total Cholesterol < 200 mg/dL < 200\text{ mg/dL} < 200 mg/dL ( 5.2 mmol/L 5.2\text{ mmol/L} 5.2 mmol/L ) 200 − 239 mg/dL 200 - 239\text{ mg/dL} 200 − 239 mg/dL ≥ 240 mg/dL \ge 240\text{ mg/dL} ≥ 240 mg/dL ( 6.2 mmol/L 6.2\text{ mmol/L} 6.2 mmol/L ) —

LDL-Cholesterol < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL ( 2.6 mmol/L 2.6\text{ mmol/L} 2.6 mmol/L )*; near optimal 100 − 129 mg/dL 100 - 129\text{ mg/dL} 100 − 129 mg/dL 130 − 159 mg/dL 130 - 159\text{ mg/dL} 130 − 159 mg/dL 160 − 189 mg/dL 160 - 189\text{ mg/dL} 160 − 189 mg/dL ≥ 190 mg/dL \ge 190\text{ mg/dL} ≥ 190 mg/dL ( 4.9 mmol/L 4.9\text{ mmol/L} 4.9 mmol/L )

HDL-Cholesterol ≥ 60 mg/dL \ge 60\text{ mg/dL} ≥ 60 mg/dL (Protective) 40 − 59 mg/dL 40 - 59\text{ mg/dL} 40 − 59 mg/dL < 40 mg/dL < 40\text{ mg/dL} < 40 mg/dL (Men) / < 50 mg/dL < 50\text{ mg/dL} < 50 mg/dL (Women) —

Triglycerides < 150 mg/dL < 150\text{ mg/dL} < 150 mg/dL ( 1.7 mmol/L 1.7\text{ mmol/L} 1.7 mmol/L ) 150 − 199 mg/dL 150 - 199\text{ mg/dL} 150 − 199 mg/dL 200 − 499 mg/dL 200 - 499\text{ mg/dL} 200 − 499 mg/dL ≥ 500 mg/dL \ge 500\text{ mg/dL} ≥ 500 mg/dL (Pancreatitis risk)

In patients with established ASCVD or very high cardiovascular risk, the target LDL-C is < 70 mg/dL < 70\text{ mg/dL} < 70 mg/dL ( 1.8 mmol/L 1.8\text{ mmol/L} 1.8 mmol/L ) or < 55 mg/dL < 55\text{ mg/dL} < 55 mg/dL ( 1.4 mmol/L 1.4\text{ mmol/L} 1.4 mmol/L ).

The NCEP ATP III Therapeutic Lifestyle Changes (TLC) Diet

Saturated Fatty Acids (SFA): < 7 % < 7\% < 7% of total daily calories. SFA (primarily palmitic C 16 : 0 C16:0 C 16 : 0 , myristic C 14 : 0 C14:0 C 14 : 0 , and lauric C 12 : 0 C12:0 C 12 : 0 acids) downregulate hepatic LDL receptor expression, reducing clearance of circulating LDL. Replace SFA with cis-monounsaturated fatty acids (oleic acid C 18 : 1 C18:1 C 18 : 1 ) and polyunsaturated fatty acids (linoleic acid C 18 : 2 C18:2 C 18 : 2 ).

Trans-Fatty Acids: Complete elimination ( < 1 % < 1\% < 1% or 0 g 0\text{ g} 0 g ). Industrial trans fats (partially hydrogenated vegetable oils) increase LDL-C, suppress HDL-C, and elevate systemic vascular inflammation.

Dietary Cholesterol: < 200 mg/day < 200\text{ mg/day} < 200 mg/day .

Total Fat: 25% to 35% of total daily energy.

Soluble Viscous Fiber: 10 − 25 g/day 10 - 25\text{ g/day} 10 − 25 g/day (within a total dietary fiber intake of 25 to 35 g/day). Soluble viscous fiber fractions (beta-glucan from oats and barley, psyllium seed husk, pectin from fruits, guar gum from legumes) bind bile acids in the intestinal lumen, accelerating their fecal excretion. This interrupts enterohepatic recirculation, forcing the liver to convert endogenous hepatic cholesterol into new bile acids, thereby upregulating hepatic LDL receptors and lowering circulating LDL-C by 5% to 10%.

Plant Stanols / Sterols (Phytosterols): 2 g/day 2\text{ g/day} 2 g/day (consumed as fortified spreads or capsules). Plant sterols possess a chemical structure nearly identical to cholesterol, competitively displacing dietary and biliary cholesterol from intestinal mixed micelles. Unabsorbed cholesterol is excreted in the feces, reducing serum LDL-C by 6% to 15% without lowering protective HDL-C.

Hypertriglyceridemia Management: For serum triglycerides > 150 mg/dL > 150\text{ mg/dL} > 150 mg/dL (and especially > 500 mg/dL > 500\text{ mg/dL} > 500 mg/dL where acute pancreatitis risk is elevated): completely eliminate alcohol; severely restrict added refined sugars, sucrose, and high-fructose corn syrup (HFCS accelerates hepatic lipogenesis); limit refined starches; reduce total dietary fat; promote weight reduction; and supplement therapeutic marine omega-3 fatty acids ( 2 − 4 g/day 2 - 4\text{ g/day} 2 − 4 g/day of EPA + DHA ), which suppress hepatic VLDL synthesis and accelerate chylomicron clearance via lipoprotein lipase activation.

  • Systemic Hypertension and the DASH Eating Plan
  • Blood Pressure Classification (2017 ACC/AHA)
  • Blood Pressure Category Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP)
  • Normal < 120 mmHg < 120\text{ mmHg} < 120 mmHg and < 80 mmHg < 80\text{ mmHg} < 80 mmHg
  • Elevated 120 − 129 mmHg 120 - 129\text{ mmHg} 120 − 129 mmHg and < 80 mmHg < 80\text{ mmHg} < 80 mmHg

Stage 1 Hypertension 130 − 139 mmHg 130 - 139\text{ mmHg} 130 − 139 mmHg or 80 − 89 mmHg 80 - 89\text{ mmHg} 80 − 89 mmHg

  • Stage 2 Hypertension ≥ 140 mmHg \ge 140\text{ mmHg} ≥ 140 mmHg or ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg
  • Hypertensive Crisis > 180 mmHg > 180\text{ mmHg} > 180 mmHg and/or > 120 mmHg > 120\text{ mmHg} > 120 mmHg

WHO (2021) and the European Society of Hypertension still define hypertension as a blood pressure of 140/90 mmHg or higher, so read which classification a question names.

Dietary Sodium Standards and Salt Equivalencies

Sodium is the primary cation of the extracellular fluid, regulating osmotic pressure and intravascular volume. In salt-sensitive hypertension, excess sodium intake expands plasma volume and elevates peripheral vascular resistance.

Standard Dietary Restriction: < 2,300 mg sodium/day < 2{,}300\text{ mg sodium/day} < 2 , 300 mg sodium/day (approx. 100 mmol 100\text{ mmol} 100 mmol or 1 level teaspoon of table salt).

Strict / Optimal Restriction: < 1,500 mg sodium/day < 1{,}500\text{ mg sodium/day} < 1 , 500 mg sodium/day (approx. 65 mmol 65\text{ mmol} 65 mmol ), recommended for adults with established hypertension, diabetes, chronic kidney disease, or individuals > 50 years > 50\text{ years} > 50 years .

Mathematical Salt Equivalency: Table salt (sodium chloride, NaCl \text{NaCl} NaCl ) is 40% sodium and 60% chloride by molecular weight:

1 g NaCl = 400 mg Sodium = 17.4 mEq Sodium 1\text{ g NaCl} = 400\text{ mg Sodium} = 17.4\text{ mEq Sodium} 1 g NaCl = 400 mg Sodium = 17.4 mEq Sodium 1 level teaspoon of salt ≈ 5.8 g NaCl ≈ 2,320 mg Sodium 1\text{ level teaspoon of salt} \approx 5.8\text{ g NaCl} \approx 2{,}320\text{ mg Sodium} 1 level teaspoon of salt ≈ 5.8 g NaCl ≈ 2 , 320 mg Sodium

Tip

In Philippine clinical practice, teach patients about high-sodium local condiments. Values vary by brand, but roughly: 1 tablespoon of fish sauce ( patis ) has about 1,400-1,500 mg sodium; 1 tablespoon of soy sauce ( toyo ) about 900-1,000 mg; 1 tablespoon of shrimp paste ( bagoong ) about 1,200-1,500 mg; and 1 bouillon cube about 800-1,100 mg. Read the label.

The DASH (Dietary Approaches to Stop Hypertension) Eating Plan

The DASH trial demonstrated that a diet rich in fruits, vegetables, whole grains, and low-fat dairy—providing generous amounts of potassium ( 4,700 mg/day 4{,}700\text{ mg/day} 4 , 700 mg/day ) , calcium ( 1,240 mg/day 1{,}240\text{ mg/day} 1 , 240 mg/day ) , magnesium ( 500 mg/day 500\text{ mg/day} 500 mg/day ) , and dietary fiber ( 30 g/day 30\text{ g/day} 30 g/day )—reduces systolic blood pressure by 8 to 14 mmHg in hypertensive patients:

Food Group Servings per Day (2,000 kcal Pattern) Nutritional Role and Clinical Significance

Grains & Grain Products 6 – 8 servings/day Emphasize whole grains (brown rice, whole-wheat bread, oats); supplies fiber and magnesium

Vegetables 4 – 5 servings/day Rich sources of potassium, magnesium, dietary nitrates, and antioxidants; promotes vasodilation

Fruits 4 – 5 servings/day High potassium and fiber; promotes natriuresis via vascular sodium-potassium ATPase

Fat-Free / Low-Fat Dairy 2 – 3 servings/day Primary source of bioavailable calcium and protein; suppresses vascular smooth muscle reactivity

Lean Meats, Poultry, Fish ≤ 6 oz (approx. 2 servings)/day \le 6\text{ oz (approx. 2 servings)/day} ≤ 6 oz (approx. 2 servings)/day Select skinless poultry and fish rich in omega-3s; avoid processed cured meats

Nuts, Seeds, and Legumes 4 – 5 servings/week Dense in magnesium, potassium, protein, arginine (nitric oxide precursor), and phytosterols

Fats and Oils 2 – 3 servings/day Use soft margarines, olive oil, canola oil; avoid butter, lard, hydrogenated shortenings

Sweets and Added Sugars ≤ 5 servings/week \le 5\text{ servings/week} ≤ 5 servings/week Restrict sweets, sugar-sweetened beverages, and sucrose-rich desserts

Congestive Heart Failure (HF) and Cardiac Cachexia

Heart failure is a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection of blood:

Compensated Heart Failure: The heart maintains adequate tissue perfusion through compensatory mechanisms (ventricular remodeling, myocardial hypertrophy, activation of the renin-angiotensin-aldosterone system [RAAS], and sympathetic nervous system discharge), without overt clinical pulmonary edema.

Decompensated Heart Failure: Compensatory mechanisms fail, precipitating severe pulmonary and systemic venous congestion, exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, hepatomegaly, ascites, and peripheral pitting edema.

Sodium and Fluid Restrictions in Heart Failure

Sodium: Standard restriction is 2,000 mg/day 2{,}000\text{ mg/day} 2 , 000 mg/day (approx. 88 mEq 88\text{ mEq} 88 mEq ). Rigid restrictions ( < 1,000 mg/day < 1{,}000\text{ mg/day} < 1 , 000 mg/day ) are no longer advised because severe palatability impairment leads to malnutrition and may cause neurohormonal overactivation.

Fluid: Restriction to 1.5 − 2.0 L/day 1.5 - 2.0\text{ L/day} 1.5 − 2.0 L/day is reserved for patients with decompensated heart failure, severe peripheral volume overload, refractory edema, or dilutional hyponatremia (serum sodium < 130 mEq/L < 130\text{ mEq/L} < 130 mEq/L ).

Cardiac Cachexia: Pathophysiology and Nutritional Repletion

Cardiac cachexia is a severe, life-threatening complication occurring in up to 10% to 15% of advanced heart failure patients (NYHA Class III and IV):

Diagnostic Definition: Unintentional, non-edematous weight loss of > 5 % > 5\% > 5% of baseline body weight over 6 to 12 months, accompanied by severe depletion of skeletal muscle (sarcopenia), adipose tissue, and somatic bone mineral density.

Etiology: Driven by a chronic neuroendocrine and hyperinflammatory storm. Elevated circulating pro-inflammatory cytokines— Tumor Necrosis Factor-alpha (TNF- α \alpha α , historically termed cachectin) , Interleukin-1 (IL-1), and Interleukin-6 (IL-6)—drive severe hypermetabolism, cellular proteolysis, and anorexia. Concurrently, right-sided ventricular failure causes splanchnic venous congestion, inducing gut mucosal edema , which produces early satiety, postprandial nausea, and cellular malabsorption of nutrients.

Nutritional Prescription:

Energy: 30 − 35 kcal/kg/day 30 - 35\text{ kcal/kg/day} 30 − 35 kcal/kg/day (based on dry, edema-free body weight) to meet elevated resting energy expenditure; can increase up to 40 kcal/kg/day 40\text{ kcal/kg/day} 40 kcal/kg/day during active repletion.

Protein: 1.2 − 1.5 g/kg/day 1.2 - 1.5\text{ g/kg/day} 1.2 − 1.5 g/kg/day dry weight to restore negative nitrogen balance and preserve diaphragmatic and skeletal muscle mass.

Meal Pattern: Small, frequent, calorie-dense feedings (6 meals/day) to prevent diaphragmatic elevation, reduce abdominal pressure, and avoid postprandial splanchnic blood pooling that precipitates hypotension and angina.

Critical Pharmacological and Micronutrient Interactions

Loop Diuretics (Furosemide, Bumetanide, Torsemide): Inhibit the Na + − K + − 2 Cl − \text{Na}^+-\text{K}^+-2\text{Cl}^- Na + − K + − 2 Cl − symporter in the thick ascending limb of the loop of Henle. Chronic aggressive administration accelerates profound urinary wasting of potassium, magnesium, and thiamin (Vitamin B 1 B_1 B 1 ​ ) .

Caution

Thiamin pyrophosphate is the essential coenzyme for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase in myocardial oxidative phosphorylation. Severe loop diuretic-induced thiamin deficiency impairs cardiac ATP generation, precipitating wet beriberi (high-output congestive heart failure and lactic acidosis), which dramatically worsens myocardial contractility. In chronic loop diuretic therapy, RNDs must advocate for thiamin supplementation ( 100 mg/day 100\text{ mg/day} 100 mg/day orally or IV).

Potassium-Sparing Diuretics (Spironolactone, Eplerenone) & ACE Inhibitors: Inhibit aldosterone receptors or angiotensin-converting enzyme, leading to potassium retention. Patients must avoid salt substitutes composed of potassium chloride (KCl) and monitor dietary potassium intake to prevent lethal cardiac hyperkalemia ( > 5.5 mEq/L > 5.5\text{ mEq/L} > 5.5 mEq/L ).